Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with ...

辉瑞公司 (PFE.US)上周六宣布，其结直肠癌治疗药物 Braftovi (encorafenib)作为联合方案的一部分，在后期试验中显示出显著的临床效果，能够缩小肿瘤大小。在公布其第三阶段 BREAKWATER 试验的数据后，这家总部位于纽约的制药巨头表示，以 Braftovi 为基础的组合药物显示出与每种药物成分先前试验一致的安全性。

智通财经APP获悉， 辉瑞 公司（PFE.US）上周六宣布，其结直肠癌治疗药物 Braftovi（encorafenib）作为联合方案的一部分，在后期试验中显示出显著的临床效果，能够缩小肿瘤大小。在公布其第三阶段 BREAKWATER 试验的数据后，这家总部位于纽约的制药巨头表示，以 Braftovi 为基础的组合药物显示出与每种药物成分先前试验一致的安全性。 其详细结果显示，Braftovi ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Snowflake in a ...

Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...

A water main break on Lawrence Street in Marietta has led to a boil water advisory for affected areas.

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...